Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough Alert! Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients
Breakthrough Alert! Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients
A recent milestone at the First Affiliated Hospital of Sun Yat-sen University in China marks a groundbreaking achievement in the treatment of relapsed and refractory multiple myeloma (R/RMM). Professor Li Juan and her team from the Hematology Department have successfully conducted the hospital’s inaugural Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) for this challenging condition, ushering in a new era of treatment prospects for R/RMM patients.
Relapsed and refractory stages are often unavoidable in the progression of Multiple Myeloma, with limited treatment options and poor prognoses for patients upon entry into this phase. CAR-T therapy, a novel precision-targeted approach in cancer treatment, involves genetically engineering T-cells to restore their functionality, effectively targeting tumors with remarkable precision, speed, and efficiency. Both domestic and international studies have shown promising results for CAR-T therapy in R/RMM patients, making it one of the most effective treatments available for this condition.
The first patient to undergo CAR-T therapy at our hospital was a 42-year-old male diagnosed with multiple myeloma two years prior at another medical institution. After undergoing conventional treatments for a period, including autologous hematopoietic stem cell transplantation, his disease unfortunately relapsed nine months post-transplant. Despite immediate intervention by experts, the disease was only briefly controlled, and the patient’s prognosis declined rapidly as he entered the refractory stage, with an estimated survival period of less than 20 months.
With the approval of China’s first CAR-T BCMA multiple myeloma product, FUCASO, the patient and his family, after thorough consultations with healthcare professionals, opted for CAR-T therapy. Prior to treatment, the hematology team meticulously discussed potential complications and collaborated with relevant departments to establish comprehensive contingency plans. Following rigorous screening, lymphocyte collection, CAR-T cell preparation, and infusion, the patient smoothly progressed through the CAR-T cell infusion stage as planned.
By the third week post-infusion, the patient experienced gradual relief from rib pain. On the 28th day post-infusion, bone marrow examination revealed no myeloma cells, and related indicators along with a full-body PET/CT scan indicated negativity for extramedullary lesions, showcasing significant treatment efficacy. The patient was successfully discharged, marking a triumphant milestone in his journey towards recovery.
According to experts, with the continuous refinement of national guidelines for CAR-T cell therapy, the formal introduction of China’s first CAR-T product for myeloma treatment offers promising prospects for extending the survival period of domestic patients with refractory and relapsed multiple myeloma.
#CARTTherapy #MultipleMyeloma #CancerTreatment #HopeForPatients #MedicalBreakthrough #Hematology #PrecisionMedicine #HealthcareInnovation #MedicalResearch #SurvivalRates
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!
**Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!**
According to the American clinical trial database Clinicaltrials, as of November 10, 2023, China has taken the lead in CAR-T cell therapy clinical research with a total of 655 studies, marking the country’s first foray into the international forefront of a new drug development field. Among them, Legend Biotech’s SicajioLunsei and Koji Pharmaceutical’s Claudin18.2 CAR-T have both achieved global leadership. Additionally, several companies are also advancing next-generation CAR-T and allogeneic CAR-T technologies, showing promising initial data and potential for global market success.
“If you’d like to inquire about the latest cancer-fighting technologies and treatments, you can contact us.”
whatsapp: 137 1795 9070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!
🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟
🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.
🌱 **The Miracle of IL-10** 🌱
The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.
🦠 **A Weapon against Relapse** 🦠
In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.
💊 **A Revolutionary Treatment Approach** 💊
These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.
✨ **A Beacon of Hope** ✨
This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer
#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough in Reducing Lupus with Successful Application of CAR-T Dual Target Technology
🌈Breakthrough in Reducing Lupus with Successful Application of CAR-T Dual Target Technology 🌟
🙌 Yin expressed her gratitude, saying: “The red spots on my body have disappeared, and I no longer need hormone medications or immunosuppressants. My mental state is also great, and all indicators are excellent. Today is my third checkup, and the results of the first two were also very positive. I thank these healthcare professionals for giving me a second life.”
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Revolutionizing Medicine: CAR-T Therapy Beyond Cancer
🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀
🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.
🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Leading Global Advances in Breast Cancer Immunotherapy
🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer
Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪
China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai
🌈🌈Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai! 🌟🌟 #CARTVictory
⚡️⚡️Lyn, a mother of three from Singapore, faced unexpected health challenges in 2022. She experienced persistent pain in her shoulders, neck, and upper limbs, disrupting her sleep and even affecting her ability to breathe. A visit to the emergency department at Shanghai Jiahui International Hospital revealed a shocking discovery – a massive tumor in her mediastinum, measuring 15 cm in diameter! The compression from this large mass not only caused excruciating pain but also impacted nearby organs such as the heart, major blood vessels, and lungs, leading to Superior Vena Cava Syndrome (SVCS). Lyn struggled with breathing difficulties, posing an imminent threat to her life.
🌸🌸The diagnosis pointed to “Primary Mediastinal Large B-cell Lymphoma,” a relatively uncommon subtype of lymphoma, prevalent among young individuals, particularly females. Despite undergoing various comprehensive treatments, including chemotherapy combined with targeted therapy and consolidative radiotherapy, Lyn unfortunately showed no response to these treatments. Eventually, the decision was made to pursue CAR-T cell therapy.
🧶🧶Lyn’s husband emphasized, “The cost of CAR-T treatment abroad is significantly higher than in China, and the waiting period is at least 3-6 months. We trust the medical expertise of China and Shanghai Jiahui. Their professionalism and meticulous care left a deep impression on us. Our decision was absolutely correct.”
💥💥 The treatment team at Shanghai Jiahui International Hospital, led by Director Vicky H. Lee and Dr. Lili Zhou, the head of the Hematology and Oncology Department, developed a meticulous treatment plan to navigate Lyn through the entire CAR-T therapy. They highlighted the critical importance of two stages: the period from cell collection to pre-infusion and the phase post-infusion, which poses a risk of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
🍁🍁 After careful preliminary treatments, infection screening, and confirmation through cell collection, Lyn received the CAR-T cell infusion. Following infusion, the “T-cell soldiers” proliferated successfully in her body, providing relief from tumor-related pain. Upon clinical assessment confirming stable conditions, Lyn smoothly transitioned to being discharged.
⛵️⛵️ It’s worth noting that CAR-T therapy costs comprise drug and non-drug expenses, with the overall treatment expenses significantly lower in China compared to Western countries. Shanghai Jiahui International Hospital collaborates with local high-quality medical resources such as Ruijin Hospital and Tongji Hospital, offering patients a comprehensive one-stop CAR-T diagnostic and therapeutic service.
#CART #SurvivorStories #MedicalMiracle #Inspiration #JiahuiInternationalHospital #CancerSurvivor #CARTTherapy #HealthJourney #advancedmedicineinchina #chinesemedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰
🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰
🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Beacon of Hope in Cancer Treatment – What is the treatment process for CAR-T cell therapy?
Beacon of Hope in Cancer Treatment
😊😊😊 What is the treatment process for CAR-T cell therapy?
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China